---
search:
  boost: 3
---

# Unspecified GI

This is a subcategory of Gastrointestinal Agents.

## Decision Trees

- [Gastrointestinal Agents - Unspecified GI - Non-Preferred](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNDhBOE5BRDUyT1Q5SkFFTkxKSUk4N1lIWiQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener" }
- [Gastrointestinal Agents - Unspecified GI- Relistor and Symproic](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUM1VRN1lWS0hYMjJCMjZLQkhVRkRRVUhDQSQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener" }
- [Gastrointestinal Agents - Unspecified GI - Aemcolo](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNUtaRFlZSDlXS0NJNEpRWjUyWFIxVVZTQSQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener" }
- [Gastrointestinal Agents - Unspecified GI - Zorbtive, Gattex](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQUwxQTRKNThJQlVTUU8xSEtFRTlBWTdXUyQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener" }
- [Gastrointestinal Agents - Unspecified GI - Step Therapy Agents](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNThUMjlYSldRVkxMTTU3R1dWNFJYOU5CTyQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener" }

## Formulary

### Preferred

| Preferred                          | Generic Name                  | Quantity | Time (Days) |
|:-----------------------------------|:------------------------------|:--------:|:-----------:|
| Amitiza <sup>ST</sup>              |                               |          |             |
| Bisacodyl                          |                               |          |             |
| Casanthranol / Docusate Sodium     |                               |          |             |
| Dicyclomine                        |                               |          |             |
| Diphenoxylate / Atropine           |                               |          |             |
| Lactulose                          |                               |          |             |
| Linzess <sup>ST</sup> 145, 290 MCG |                               |          |             |
| Loperamide                         | Loperamide HCI Cap & Tab 2 MG |    80    |     34      |
| Lubiprostone <sup>ST</sup>         |                               |          |             |
| Movantik <sup>ST</sup>             |                               |          |             |
| Polyethylene Glycol                |                               |          |             |
| Psyllium Fiber                     |                               |          |             |
| Senna                              |                               |          |             |
| Trulance <sup>ST</sup>             |                               |          |             |
| Xifaxan <sup>ST</sup>              |                               |          |             |

### Non-Preferred

| Non-Preferred                                                                           | Generic Name | Quantity | Time (Days) |
|:----------------------------------------------------------------------------------------|:-------------|:--------:|:-----------:|
| Aemcolo                                                                                 |              |          |             |
| Gattex                                                                                  |              |          |             |
| Ibsrela                                                                                 |              |          |             |
| Linzess 72 MCG                                                                          |              |          |             |
| Motegrity                                                                               |              |          |             |
| Mytesi                                                                                  |              |          |             |
| Relistor                                                                                |              |          |             |
| Symproic                                                                                |              |          |             |
| Zorbtive                                                                                |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days except 3 days for Aemcolo

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response to at least ^^14 days^^ with at least ^^two preferred^^ drugs

[**Xifaxan Guidance](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Medication%20Guidance/xifax/?h=xifax)</br>
[***Amitiza/Lubiprostone Processing Guidance](https://special-spoon-f542dccd.pages.github.io/Pharmacist%20Reference%20Guide/Clinical%20and%20PA%20Notes/amitiza/?h=amit)

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^14 days^^ with at least ^^three preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Methylnaltrexone (Relistor) and Naldemedine (Symproic)

Additional Methylnaltrexone (Relistor) and Naldemedine (Symproic) Criteria

- Must have a history of chronic pain requiring continuous opioid therapy for â‰¥84 days

### Rifamycin Delayed-Release (Aemcolo)

Additional Rifamycin Delayed-Release (Aemcolo) Criteria

Must have the inability to take, or failure of **ALL** of the following: azithromycin,
ciprofloxacin, levofloxacin, ofloxacin, or rifaximin

### Somatropin Injection (Zorbtive) and Tedloglutide (Gattex)

Additional Somatropin Injection (Zorbtive) and Tedloglutide (Gattex) Criteria

- Must have evidence of specialized parenteral nutritional support
- Must have documentation of appropriate lab assessment (bilirubin, alkaline phosphatase, lipase, and amylase) at least 180 days prior to initiation

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., decreased frequency of specialized nutrition support or improvement in symptoms)

## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=64&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){:target="_blank" rel="noopener"} </br>
[Criteria](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20criteria%20effective%2001.01.2024.pdf#page=74){ :target="_blank" rel="noopener"} </br>
[Preferred Drug List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/UPDL%20effective%2001.01.2024.pdf#page=24){ :target="_blank" rel="noopener"} </br>
[Quantity Limit List](https://spbm.medicaid.ohio.gov/SPDocumentLibrary/DocumentLibrary/UPDL/Quantity%20Limits.pdf){ :target="_blank" rel="noopener"}
